Dr. David Spellmeyer Joins Chemical Computing Group's Scientific Advisory Board.

MONTREAL, and PALO ALTO, Calif., June 19 /PRNewswire/ --

Chemical Computing Group Inc. (http://www.chemcomp.com) today announced Dr. David Spellmeyer, Executive Director DuPont Pharmaceuticals, as the newest member of its Scientific Advisory Board. Dr. Spellmeyer joins current SAB members: Dr. Jurgen Bajorath (NCE Inc. -- Seattle, WA), Dr. Gordon Crippen (University of Michigan -- Ann Arbor, MI), Dr. Eric Martin (Chiron Corporation -- San Francisco, CA) and Dr. William Ripka (Ontogen Inc. -- Carlsbad, CA). CCG's Scientific Advisory Board acts in an advisory capacity and assists the company in both current product development and in establishing future product direction.

"We are delighted to have David as a member of our SAB. CCG has enjoyed and benefited from its interactions with David from the inception of the company," stated Paul Labute, President and CEO of CCG. "We welcome his input as we continue to increase MOE's (Molecular Operating Environment) breadth and scope and look forward to working with him and the other SAB members as CCG develops total solutions for the drug discovery community."

Dr. Spellmeyer is Executive Director of Computational Sciences at DuPont Pharmaceuticals. Prior to this he has held positions at CombiChem, Chiron and Dupont Medical Products. He received his Ph.D. in 1987 from UCLA followed up by a 2-year post-doctoral term in pharmaceutical chemistry at UCSF. He continues his interaction with the UCSF research groups through his adjunct assistant professorship. His research interests include conformational analysis, computational aspects of combinatorial chemistry, ligand-protein interactions, and medicinal chemistry. He is an author of over 35 scientific publications, frequently makes presentations at scientific seminars and is an author of two modeling packages.

"I am very pleased to be asked to join Eric, Bill, Jurgen, and Gordon on CCG's advisory board. From its beginnings, CCG has been focused on delivering state-of-the-art applications and solutions to drug discovery researchers. I have had many opportunities over the years to interact with their scientists and developers as CCG has evolved into a well respected developer and supplier of drug discovery software solutions. I look forward to working with them and the other SAB members as the company tackles the exciting challenges facing pharmaceutical and biotechnology researchers."

MOE is the next generation of chemical computing software. MOE delivers built-in out-of-the-box applications, source code for easy adaptation and an embedded language platform for rapid methodology application prototyping. It is also the only true platform-independent software package that allows researchers to choose the platform that best meets their needs and resources. This marriage of unique architecture and platform independence makes MOE the ideal candidate for corporate deployment from methods developer to computational applications scientist to medicinal chemist. Its next generation flexibility and customizability ensure that the software package changes and grows as the science changes and grows.

MOE's built-in applications cover a wide range of research areas including: High Throughput Screening Data Analysis, Combinatorial Chemistry Library Design, and Protein & Homology Modeling as well as molecular modeling and simulation.


Bill Hayden, Vice President

514 393 1055 - phone

514 874 9538 - fax



Terms of use | Copyright © 2017 Farlex, Inc. | For webmasters